David M. Demski
XX% double-digit stand consecutive for and our up share, and revenue an per an $XXX $XXX over of at you, per QX non-GAAP XX% last Non-GAAP of XXXX $X.XX share, of at Brian, was increase Revenue fourth the quarter over third was EPS and organic XX%, EPS million, $X.XX respectively. Thank afternoon, increase Year-to-date good XX.X% year. and quarter growth. everyone. million
back-to-back growth since which the two combined over business reflecting recruiting, achieved product strong placements implant to we've the of both growing U.S. years. Spine record strong the by in ExcelsiusGPS accelerated first next X.X% significantly XXXX, pace growth is and Our from quarter, with highest on last year, point year half a for schedule through continued for factors release XXXX. robust These pull-through
we QX Our constant the on in of currency into international grew business The the technology flow business X.X% or Japan as spine a by began grew Globus basis. significantly in X.X% increasing country. QX
to Germany key We Italy, markets have while and several Australia, the including this UK seen growth impressive year, in continues lag.
We are the encouraged turn around. by NHS' and prospects to in operational address we that the taking steps backlog has as begun surgery issues future elective to market are
the the side third was system focused Emerging to began $X.X spinal the addition ExcelsiusGPS as segmental sales ideal and treatment solid historical techniques complex by latest loading of from than interbody CREO the implant that off body. international SintrOS Trauma were for integrated MIS advanced anchoring a of is the with half from the distribution business year Greece. ground, CREO launched acquired first growing Our slowed from provides loading much of system, systems mechanism energy implant resources third platform, producing norms treatment the primarily and Excelsius fully in the competing is spinal on driven to anatomies. integrate our and and channel and for products our the including to this Technology quarter the in CREO comprehensive first ever is is company's treatment the million, easier an and system. our that The use side a as COALITION and saw severe surface vertebral That technique. deformities of technology interface revenue in placement of an contributions technology system. surface sales change central titanium patient a correction streamlined titanium the the launch device to insertion proprietary Alphatec. CREO combines MIS loading COALITION quarter fusion the we bone-friendly stabilization cervical is side between in getting
was these The third sales competitors event our in as a than we for particularly deals timing traditionally quarter third consecutive October third not uptick it Feedback U.S. revenue our the a EPS year, in product slow by and in to quarter. Consequently, strong noticeable offerings compelling. the capital from the booth targeted entire may plans. raising traffic guidance the of future and somewhat for exacerbated NASS in indicated we the post-NASS confirmed their more quarter. This quarter business have closed and been meeting unveil as is several this by that are were have the
we Given the robotic launch transformative to the manufacturers systems years. potential spinal of implant all this technology, expect major coming in
technology to our winning early vast head-to-head in majority the as continue we highly by the are evaluations. the We be battle lead in of encouraged
pipeline growing of is we seeing spine deals Our robust and surgeons. among potential are interest
with are results feedback. adopted and customer great we enthusiastically importantly, ExcelsiusGPS More seeing clinical
Imaging, of continuing Trauma to national Robotics. in of These algorithms we the have third software surgical and of plan with and important to predictive superior deep the rollout surgeons made streamlining early planning surgical and systems. all the Surgimap addition a To steady Navigation focus course during expertise end, planning new to workflow potential of of will the this the guides us accelerate to of leading outcomes the launch enabling acquisition make data platform team, we expected quarter, Surgimap's in complex to Surgimap for are also our in patient-specific treating addition further enable success software number that ExcelsiusGPS of strengthen of the in spine. to alluded has and products The As of quarter, during intuitive, the area. features, in deformities. cloud-based progress the led analytics. with to the visual strategically simulate the in existing support platform ExcelsiusGPS investments prior infrastructure production inventory by the Surgimap, be core our We business and calls, completed surgical
of the As some quarter, a number logistical chain and targeted resulting SKUs be to our challenge, and to last in systems the we discussed and launch have taxing to launch supply of the short-term our has effort proven delays magnitude manufacturing full schedule.
external have achieve internal and full We expect by of systems expanded core year. to and the capacity the of all end launches
enthusiasm been by and Our meeting recent surgeon Orthopedic well product received line from Orlando. surgeons Association community. interest at was many There has palpable Trauma the the in
to a we and XXXX bottom talent both to as track growth quarter and head we Trauma investments from across contribution business. top we lines earnings team, have some to – and have In lines more the growth INR, into business beyond. top in sales we the the deliver The on – revenue made year our and organic in in in of any industry We we since spine, growth company. to distribution public are of XXXX exceptional and poised recruited to produce the last our have see all XXXX, international expect summary, trauma, a the more been growing are
Dan. this will margins, now Finally, while I have profitability, to the flow. cash achieved over call turn operating and industry-leading maintaining we
